Product category:
Cell/tissue handling and counting
News Release from: Microbix Biosystems
Edited by the Laboratorytalk Editorial
Team on 02 July 2003
Patent filed for new vaccine technology
platform
New proprietary vaccine technology platform is said to have the potential to offer significant economic advantages to vaccine producers
Microbix Biosystems has announced filing of a patent for a new proprietary vaccine technology platform that it says has the potential to offer significant economic advantages to vaccine producers The company filed for the patent, with the intent of establishing exclusive rights on a global basis, after successfully concluding feasibility studies
This article was originally published on Laboratorytalk on 20 Mar 2003 at 8.00am (UK)
Related stories
Double anniversary at Focus
Supplier of one quarter of the world's haematology analysers celebrates its twentieth birthday, while its parent company celebrates its fiftieth
Merger of HTP operations
"With a combined instrumentation and biochemistry team we can respond faster and more flexibly to the assaying demands of current and future customers"
Its new technology is the result of nearly three years of development work, reports William J Gastle, president and CEO, "and is the second potential large market biologic to be advanced to the licensing stage since ThromboClear, which was successfully partnered in 2002." Gastle said this technology has the potential to further diversify Microbix's future revenue stream and that the company is now in the process of assembling the data necessary to commence discussions in the autumn with potential pharmaceutical partners interested in licensing the technology.
The news follows earlier reports by the company that it would be making an announcement in the third quarter about a second large market product in its pipeline.
Further news will be issued as the size and timing of the opportunity is established, Gastle said.
Microbix specialises in developing and manufacturing tissue culture- derived biologicals for an emerging world market for biotherapeutic drugs and vaccines.
It makes reagents for building diagnostic products and tools used in biotechnology research.
It claims expertise in advanced culture, purification and process validation technologies.
Its objective during the next decade is to become a major force in what is expected to be a multi- billion generic biotherapeutics market in North America.
• Microbix Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
